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Abstract
Background: Bacterial infection is a well-known risk of breast implant surgery. It is typically caused by bacterial skin
flora, specifically Staphylococcus aureus and the coagulase negative staphylococci. There have been infrequent
reports of breast implant infection caused by the atypical mycobacteria, of which Mycobacterium canariasense not
yet reported in the literature.
Case presentation: This report summarizes the case of a female patient who underwent mastectomy followed by
bilateral breast augmentation and presented approximately three years later with clinical evidence of infected
breast prosthesis by Mycobacterium canariasense. One year after thoroughly follow-up, appropriate antibiotherapy
and the change of the infected prosthesis, the patient presented no signs of reinfection.
Conclusion: Our case demonstrates that Mycobacterium canariasense should be considered as a new potential
cause of infected breast prosthesis.
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Background
Breast implant-associated bacterial infections occur in 2.0
to 2.5% of cosmetic cases and up to 20% of reconstructive
cases [1]. Infections caused by mycobacteria are uncom-
mon, but are being increasingly reported [2-5]. However,
breast implant infections caused by Mycobacterium canar-
iasense are atypical and not yet reported in the literature.
We report here the case of a female patient who
underwent mastectomy followed by bilateral breast aug-
mentation and presented approximately three years later
with clinical evidence of infected breast prosthesis by
Mycobacterium canariasense. The complexities estab-
lished in the diagnosis and need for a thorough and accur-
ate microbiologic evaluation, as well as the management
strategies are summarized in the case report and discus-
sion that ensue.
Case presentation
A 44-year old healthy woman was operated on May
2006, of bilateral mastectomy for an invasive lobular car-
cinoma and associated in situ lobular carcinoma in the
left breast. On the left side, a skin sparing radical modi-
fied mastectomy was performed, and on the right side a
prophylactic nipple sparing simple mastectomy was
done. Mastectomy was followed by bilateral breast aug-
mentation with Mentor prosthesis (Mentor Worldwide
LLC, California, USA) filled with 150 mL saline serum,
the prosthesis was inserted behind the pectoral muscles.
Prophylactic antibiotherapy with amoxicillin and cla-
vulanate 2 g/day was prescribed for 10 days. The patient
received later on, chemotherapy and radiotherapy treat-
ment. Two years later, she had her Mentor® prosthesis
changed with a similar new one filled with 110 mL of
gel and 215 cc of saline serum for unsatisfactory esthetic
results. Valves were inserted on the lateral thoracic wall.
Augmentin® (amoxicillin and clavulanate) was given
intravenously 30 minutes before surgery and then was
continued for 10 days.
As a follow-up, she was seeing her plastic surgeon on
a regular basis and her prosthesis were progressively
filled with saline serum through the valves. Her postop-
erative course was uneventful until January 2009, when
she presented with edema and redness of her right breast
after valve ablation, without pus drainage nor fever. She
was treated with empiric antibiotherapy (Augmentin® 2 g/
day and ciprofloxacin 500 mg twice daily) for 10 days and
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received local care. Her serum white blood cell count was
6,000 (neutrophils of 81%). Consequently, since she had
no improvement of her symptoms, she underwent re-
moval of her right breast implant with capsulectomy and
massive irrigation with bacitracin and 9 liters of saline
serum, then new prosthesis re-implantation.
Serous fluid drained from her right breast was sent to
culture, as well as the capsule and the whole prosthesis.
Gram stain, aerobic and anaerobic cultures of the fluid,
prosthesis, and breast tissue returned negative. Histo-
pathological examination of the breast capsule revealed
none specific inflammatory changes without identifying
any germ. Fungal culture returned negative as well after
40 days of incubation. Furthermore, acid-fast stain of the
fluid drained from the right breast, debridement tissue,
and the prosthesis returned negative. Acid-fast culture
of the fluid, and of the resected right breast tissue were
also negative, while acid-fast culture of the ablated pros-
thesis were positive, it revealed the presence of an acid-
fast bacilli resembling to Mycobacterium tuberculosis. A
swab culture of the periprosthetic space – the space be-
tween the prosthesis and the breast wall – as well as a
definitive mycobacterial culture of the unidentified patho-
gen isolated from the prosthesis in the initial laboratory
were sent to the National Reference Center on Mycobac-
teria of Pitié-Salpêtrière hospital in Paris, France. The anti-
microbial susceptibility testing of the pathogen were
obtained from Rapid Growing Mycobacteria Plate Format
(RAPMYCO) Sensititre plates in Mueller-Hinton medium
incubated for 7 days. The identification was done by se-
quencing the gene of the Heat Shock Protein (HSP) and
revealed the presence of M. canariasense in the prosthesis
and the peri-prosthetic space.
Subsequently, the patient received post-operatively
empirical antibiotherapy including vancomycin 1 g every
12 hours, Tienam® (imipinem/cilastatin) 500 mg every
6 hours, and Tavanic® (levofloxacin) 500 mg/day, for
10 days. She was then discharged on oral tritherapy: cip-
rofloxacin, Bactrim® (sulfamethoxazole and trimetho-
prim) and clindamycin for 6 months, after the culture
revealed the presence of an atypical Mycobacterium. The
first two antibiotics were prescribed based on the anti-
biogram’s results (Table 1). However, clindamycin was
prescribed by the infectious disease specialist without
Table 1 Antimicrobial susceptibility of Mycobacterium canariasense - Antibiogram as performed in Paris, France
Antibiotic Susceptibility Minimum inhibitory
concentrations (mg/L)
Pharmaceutical form (in case of pathogen’s
sensitivity to the antibiotic)
Amoxicillin + clavulanic acid R 64.00 -
Cefoxitin S 16.00 Powder for solution for injection, IV
Ceftriaxone R > 64.00 -
Imipenem I 8.00 -
Streptomycin S 2.00 Powder for solution for injection, IM/IV
Tobramycin S 2.00 Inhalation powder
Ophthalmic ointment and solution
Powder for solution for perfusion
Amikacin S 2.00 Powder for solution for injection
Minocycline I 2.00 -
Tigecycline S 0.02 Powder for solution for injection
Clarithromycin S 1.00 Per os, not available in Lebanon
Cotrimoxazole (sulfamethoxazole + trimethoprim) S 1.00 Per os, prescribed to the patient
Powder for solution for injection or infusion
Ciprofloxacin S 0.50 Ophthalmic ointment and solution
1.00 Per os, prescribed to the patient
Solution for auricular instillation
Solution for perfusion, IV
Ethambutol S <0.50 Per os, not available in Lebanon
Solution for injection
Rifabutine R 1.00 -
Linezolide S 4.00 Per os, not available in Lebanon
Solution for perfusion
I: intermediate; IM: intramuscular; IV: intravenous; R: resistant; S: sensitive.
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performing clindamycin susceptibility testing. The patient
was last seen in March 2014. She was symptom-free, with-
out signs of infection and achieved a satisfactory psycho-
logical, psychosocial and esthetic results.
Conclusions
Breast prostheses are being increasingly used, both for
cosmetic and reconstructive purposes [3]. However, peri-
prosthetic infection is perhaps the most feared and least
understood complication of these procedures [3]. Al-
though bacteria such as Staphylococcus aureus, coagulase-
negative staphylococci and mycobacteria such as Myco-
bacterium fortuitum complex are the most common cause
of surgical site infections [3,4,6], this case highlights the
emergence of atypical and unusual M. canariasense as
pathogen associated with breast implant infections. Our
review of the literature has produced no similar breast im-
plant infection.
M. canariasense is a member of the rapidly growing,
non-pigmented and atypical mycobacterium group. The
characterization of this mycobacterium, in 2004, was
based on a cluster of strains isolated from blood cultures
via indwelling catheters from patients with probable noso-
comial infection in the Canary Islands, Spain [7,8]. It was
also isolated from respiratory sources but the pulmonary
infection was deemed possible to doubtful in a patient pri-
mary diagnosed with cancer [9].
Regarding management of breast implants’ infections,
although prospective studies are lacking, published re-
ports recommend that the mammary prosthesis be re-
moved, with earlier removal favored to prevent implant
extrusion and tissue contracture [10]. Besides, the best
conservative treatment of the implant seems to be the as-
sociation of implant change, irrigations and antibiotherapy
[11]. These procedures were substantially performed in
our case.
Although the cause of breast implant infections might
not be truly understood, the challenge is how to treat
them appropriately. Classic teaching holds that peripros-
thetic infection mandates implant removal and delayed
reinsertion after the infection clears [12]. However, the
first report of immediate salvage of infected breast pros-
theses after complete mastectomy for cancer was by Yii
and Khoo in 2003 [13]. Similarly, a more recent study by
Chun et al. revealed that eight (100%) patients had posi-
tive outcomes following the immediate salvage [12]. In
the latter case series, the author reported that the cul-
tures of the periprosthetic fluid of the infected implants
were positive for Staphylococcus aureus in three patients
and Enterococcus faecalis in one patient. A fifth patient
was positive for Staphylococcus epidermidis [12]. In our
case, given that the patient insisted to conserve her es-
thetic results, she was given the choice of delayed or im-
mediate re-implantation. At that stage of time, the causal
agent of the infection was not yet identified as a rapidly
growing mycobacteria. In close, she decided to undergo
the one-stage re-implantation although she was aware of
the risk of infection recurrence. Consequently, early and
aggressive surgical intervention resulted in successful
immediate implant salvage. It is worthy to note that de-
layed re-implantation may have major psychological im-
plications for the patient. To many women suffering with
breast cancer, breast reconstruction is a critical compo-
nent in the recovery process. Explantation halts the recon-
struction process for upward of 6 months. In this context,
one of the goals of the immediate re-implantation is to
improve women’s psychological well-being.
On the other side, despite the continuous evolution of
mycobacterial taxonomy which may represent a source
of confusion for laboratories and clinicians, and which
may not be identified by conventional procedures, we
were able in our settings to identify the atypical M.
canariasense. In fact, definitive diagnosis of mycobacter-
ial breast implant infection requires demonstration of
the organism from the periprosthetic site. Thus, speci-
mens must be submitted for acid-fast stains fungal and
mycobacterial culture, in addition to standard analyses,
including Gram-stain, bacterial aerobic and anaerobic
culture, and histopathology [3]. In this case, it was only
after multiple specimens of the fluid drained from the
right breast, debridement tissue, and the prosthesis were
sterile on routine bacterial and fungal cultures, that the
possibility of an atypical infection such as a mycobac-
terial process was considered. Subsequent specimens
submitted for mycobacterial culture from the ablated
prosthesis identified the causative pathogen, M. canaria-
sense. Therefore, we prescribed a prolonged course of
anti-mycobacterial therapy that allowed for eradication of
the infection.
Moreover, empiric antimicrobial therapy was started in
our case pending isolation and susceptibility testing re-
sults. Of note, in the study of Xiang et al., the results
of the antimicrobial susceptibility of M. canariasense
showed that this agent is sensitive to amikacin, imipe-
nem, ciprofloxacin and trimethoprim-sulfamethoxazole. It
is intermediately susceptible to cefoxitin. However, it is
resistant to clarithromycin and minocycline [9]. With
this knowledge, our patient was discharged on ciproflox-
acin, clindamycin and sulfamethoxazole-trimethoprim,
after the culture revealed the presence of M. canariasense.
We stress the point that clindamycin was empirically
prescribed by the infectious disease specialist although
nontuberculous mycobacteria (NTM) generally are not
susceptible to this agent. He aimed to cover a large
spectrum of infectious agents due to the non-conventional
diagnosis and management of our patient. In the end, the
treatment provided anti-bacterial coverage for the re-
implanted prosthesis for 6 months.
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In conclusion, the theme of this article is to share a
successful one-stage replacement of infected breast pros-
thesis by atypical NTM after mastectomy reconstruction.
The surgical and pharmacological management of the
patient was successful given the very good esthetic re-
sults in the patient. Our case also reminds us that a high
index of suspicion for unusual pathogens, such as the
atypical mycobacteria, is necessary when considering
infections that do not improve despite seemingly ap-
propriate management. Moreover, it demonstrates that
M. canariasense should be considered as a new po-
tential cause of infected breast prosthesis.
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